Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up

BACKGROUND: Dimethyl fumarate and fingolimod are oral disease-modifying therapies approved to treat relapsing multiple sclerosis. Prior observational studies and our previous 12-month investigation showed comparable clinical efficacy. OBJECTIVE: The purpose of this study was to assess real-world eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hersh, Carrie M, Love, Thomas E, Bandyopadhyay, Anasua, Cohn, Samuel, Hara-Cleaver, Claire, Bermel, Robert A, Fox, Robert J, Cohen, Jeffrey A, Ontaneda, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574489/
https://www.ncbi.nlm.nih.gov/pubmed/28890796
http://dx.doi.org/10.1177/2055217317715485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574489/
https://www.ncbi.nlm.nih.gov/pubmed/28890796
http://dx.doi.org/10.1177/2055217317715485

Ejemplares similares